AALP ApoA1 measures the main protein on HDL—often called the “good cholesterol.” It’s part of the HDL Function Panel, which looks at how well your HDL works, not just how much HDL cholesterol you have. This test uses an advanced lab method and reports results in nmol/L (not mg/dL like the standard ApoA1 test). Why it matters HDL helps protect your heart by picking up extra cholesterol from artery walls and carrying it to the liver for removal (this is called cholesterol efflux). ApoA1 is the “workhorse” protein that helps HDL do that job. Higher AALP ApoA1 generally suggests HDL is working better. Lower AALP ApoA1 can mean HDL isn’t removing cholesterol as effectively—even if your regular HDL cholesterol number looks “normal.” Typical reference ranges (nmol/L) Men: 181–359 nmol/L Women: 215–421 nmol/L These values use a different method and cannot be compared to the standard ApoA1 test reported in mg/dL. How the lab measures it The lab enriches HDL particles that carry ApoA1 and then measures the proteins on them with a precise mass-spectrometry method. The results contribute to models that estimate HDL function and a heart artery disease risk score (HDLfx pCAD Score). How to read your result If your AALP ApoA1 is higher (within or above the reference range): This often points to better HDL function and lower heart disease risk, especially when other markers agree (healthy LDL/ApoB, lower triglycerides, good blood sugar, and a favorable HDL Function Panel score). If your AALP ApoA1 is lower: This may reflect less effective HDL function. It’s commonly seen with insulin resistance, extra weight around the middle, higher triglycerides, or ongoing inflammation. Your clinician will look at AALP ApoA1 alongside your LDL/ApoB, triglycerides, blood pressure, blood sugar, and the rest of the HDL Function Panel. What can influence AALP ApoA1 Metabolic health: Insulin resistance, central weight gain, and high triglycerides can weaken HDL’s performance. Inflammation or illness: Ongoing inflammation can reduce HDL’s protective effects. Medications & lifestyle: Statins, fibrates, niacin, GLP-1/weight-management therapies, exercise, and nutrition changes can shift HDL function (effects vary by person). How this fits into the HDL Function Panel AALP ApoA1 is one of several HDL-related proteins measured together. These results help calculate: Predicted cholesterol efflux (pCEC): an estimate of how well your HDL removes cholesterol. HDLfx pCAD Score: a score that helps your clinician judge artery-disease risk even when standard cholesterol looks okay. No single result diagnoses heart disease. Your provider interprets this marker in context with your history, exam, and other tests. What to do next (practical steps) Bring your report to your clinician and review AALP ApoA1 with your LDL/ApoB, triglycerides, blood pressure, blood sugar (A1c), and the full HDL Function Panel. Ask about targets and follow-up: Should you focus on weight management, triglyceride reduction, or inflammation control? Lifestyle basics that support HDL function: Routine aerobic + resistance exercise Weight management (especially waist circumference) Triglyceride-friendly eating (reduce added sugars and refined carbs; emphasize fiber-rich plants, lean proteins, and unsaturated fats) Sleep, stress, and smoke-free living Medication review: If you’re on statins or other therapies, ask whether adjustments could help your overall risk profile. FAQs Is AALP ApoA1 the same as the standard ApoA1 test? No. The standard test measures all ApoA1 in mg/dL. AALP ApoA1 measures ApoA1 on HDL particles using a different method and reports nmol/L. The numbers can’t be compared. If my AALP ApoA1 is “good,” am I protected? It’s a positive sign, but heart risk depends on many factors. Your clinician will interpret this result with your other labs and your overall health picture. Why would my AALP ApoA1 be low if my HDL cholesterol is normal? HDL function and HDL quantity don’t always match. This test helps explain that mismatch and can guide more personalized prevention.
Ab NK (CD56/16) refers to the antibody staining of natural killer (NK) cells to detect the presence of specific surface markers, CD56 and CD16. CD56 is a neural cell adhesion molecule, and CD16 is an Fc receptor. Ab NK (CD56/16) analysis is crucial in identifying and characterizing different subsets of NK cells, including the CD56bright and CD56dim populations, each with distinct functional roles in the immune system. CD56bright NK cells are known for their regulatory functions and cytokine production, while CD56dim NK cells are associated with cytotoxic activities and antibody-dependent cell-mediated cytotoxicity (ADCC). The assessment of Ab NK (CD56/16) provides valuable insights into the composition and function of NK cells, contributing to a better understanding of immune responses and potential implications in various health conditions.
AB42/AB40 Ratio: A Critical Biomarker in Alzheimer’s Disease Diagnosis The AB42/AB40 ratio is an advanced cerebrospinal fluid (CSF) biomarker that measures the balance between β-Amyloid (1-42) and β-Amyloid (1-40), two peptides derived from the amyloid precursor protein (APP). This ratio plays a crucial role in diagnosing Alzheimer’s disease (AD) and differentiating it from other neurodegenerative or dementia-related conditions. What Is the AB42/AB40 Ratio? β-Amyloid (1-42): This peptide aggregates in the brain to form amyloid plaques, a hallmark of Alzheimer’s disease. Reduced levels in CSF reflect its deposition in the brain. β-Amyloid (1-40): The most abundant amyloid peptide in CSF, it remains relatively unaffected by plaque formation and serves as a stable reference for total amyloid production. The AB42/AB40 ratio normalizes the levels of β-Amyloid (1-42) to β-Amyloid (1-40), providing a more reliable measure of amyloid plaque burden. This ratio reduces the impact of individual variability in amyloid production and factors such as CSF protein levels or sample dilution. Reference ranges of AB42/AB40 Ratio: The reference range for the AB42/AB40 ratio can vary depending on the laboratory and assay method used, but generally, the following thresholds are applied: Normal Range (Low Risk for Alzheimer’s): ≥ 0.16 This indicates a healthy balance of β-Amyloid (1-42) and β-Amyloid (1-40), with no significant amyloid plaque deposition. Abnormal Range (High Risk for Alzheimer’s): < 0.16 A reduced ratio below this threshold strongly suggests amyloid plaque formation in the brain and is commonly associated with Alzheimer’s disease. Some studies or labs may use slightly different cutoffs, such as 0.068, particularly in research settings or based on assay-specific validations. Always interpret results in the context of additional biomarkers (e.g., total tau, pTau) and clinical findings. Clinical Implications of a Reduced AB42/AB40 Ratio 1. Alzheimer’s Disease Diagnosis A low AB42/AB40 ratio is strongly indicative of Alzheimer’s disease, reflecting the sequestration of β-Amyloid (1-42) in brain plaques. Ratios below 0.068 are typically associated with a high likelihood of Alzheimer’s pathology. 2. Differentiating Alzheimer’s from Other Conditions The AB42/AB40 ratio is more specific to Alzheimer’s disease than β-Amyloid (1-42) alone, helping to distinguish it from other dementias or neurodegenerative disorders like vascular dementia or frontotemporal dementia. 3. Mild Cognitive Impairment (MCI) In individuals with MCI, a reduced AB42/AB40 ratio suggests a higher risk of progression to Alzheimer’s disease, allowing for earlier intervention. Benefits of the AB42/AB40 Ratio Improved Diagnostic Accuracy: The ratio is less influenced by individual variability in β-Amyloid production compared to β-Amyloid (1-42) alone. Early Detection: Changes in the AB42/AB40 ratio often precede the onset of cognitive symptoms by years. High Sensitivity and Specificity: Studies have shown the ratio to have 77% sensitivity and 85% specificity for Alzheimer’s disease diagnosis. Next Steps After a Reduced AB42/AB40 Ratio If the AB42/AB40 ratio is reduced, further diagnostic evaluations may include: Tau Protein Testing: To assess neuronal damage (total tau) and tau hyperphosphorylation (pTau). Imaging Studies: Such as amyloid PET scans to visualize amyloid plaques in the brain. Cognitive Testing: To evaluate memory and cognitive function. By combining the AB42/AB40 ratio with other biomarkers, clinicians can achieve a more accurate and early diagnosis of Alzheimer’s disease, facilitating effective treatment and care planning. This biomarker is a vital tool in understanding Alzheimer’s disease progression, offering insights into amyloid plaque burden and distinguishing it from other conditions. Early identification through the AB42/AB40 ratio provides an opportunity for timely intervention and better patient outcomes.
Aβ42/40 Ratio (Amyloid Beta 42/40 Ratio) What it is: The Aβ42/40 ratio measures the levels of two forms of amyloid beta proteins—Aβ42 and Aβ40—in your blood or cerebrospinal fluid (CSF) and calculates their ratio. These proteins are naturally produced in the brain, but an imbalance—especially a lower Aβ42/40 ratio—is one of the earliest and most reliable indicators of Alzheimer’s disease. Why it matters: In Alzheimer’s disease, Aβ42 tends to clump into plaques in the brain, causing its levels in blood or CSF to drop relative to Aβ40. A reduced Aβ42/40 ratio is therefore considered a strong marker of amyloid plaque accumulation, which is a hallmark of early Alzheimer’s pathology—often before cognitive symptoms are noticeable. Who it's for: This test is used primarily in people experiencing memory loss or cognitive changes, or those at higher risk of Alzheimer’s due to family history or age. It’s also valuable for healthcare providers looking to confirm the presence of amyloid-related pathology in patients being evaluated for dementia. Clinical insights: A low Aβ42/40 ratio is associated with early-stage Alzheimer’s disease and can distinguish it from other types of dementia. The test is often used alongside tau protein biomarkers (like p-tau181 or p-tau217) to improve diagnostic accuracy. May support eligibility or monitoring in clinical trials or treatment programs targeting amyloid-related pathology. Takeaway: The Aβ42/40 ratio provides critical insight into your brain's amyloid status. When used with other cognitive and biomarker tests, it offers a clearer picture of Alzheimer’s risk and progression, helping you and your care team make proactive, informed decisions about your brain health.
part of a blood test called "Protein Electrophoresis"
measures the absolute count of CD8 positive suppressor T-cells
The biomarker "Abs.CD19+ Lymphs" in the T + B-Lymphocyte Differential panel from Labcorp measures the absolute count of CD19 positive lymphocytes, which are primarily B cells. CD19 is a marker indicating B cell presence, crucial for the adaptive immune response, especially in antibody production. This absolute count provides a specific numerical value rather than a percentage, offering a direct measure of the B cell population in the blood. It's instrumental in diagnosing and monitoring conditions affecting B cell function, such as immunodeficiency disorders, certain types of leukemia, and autoimmune diseases. Understanding variations in these counts is vital for evaluating the immune system's health and function.
CD25 is the receptor for IL2 and is expressed on activated T cells, B cells, and macrophages. CD25 is expressed in certain types of B-cell lymphoma (hairy cell leukemia) and T-cell lymphoma (adult T-cell lymphoma/leukemia [ATLL]). The interleukin-2 receptor is designated CD25. Originally isolated from T-lymphocytes, it is now known to be expressed on hairy cell leukemia and adult T-cell leukemia/lymphoma, classical Hodgkin lymphoma, and a subset of other peripheral T-cell lymphomas. General information: Lymphocytes in peripheral blood (circulation) are heterogeneous and can be broadly classified into T cells, B cells, and natural killer (NK) cells. There are various subsets of each of these individual populations with specific cell-surface markers and function. This assay provides absolute (cells/mcL) and relative (%) quantitation for the main categories of T cells, B cells, and NK cells, in addition to a total lymphocyte count (= CD45+). - Each of these lymphocyte subpopulations have distinct effector and regulatory functions and are maintained in homeostasis under normal physiological conditions. - Each of these lymphocyte subsets can be identified by a combination of one or more cell surface markers. T-cell: The CD3 antigen is a pan-T-cell marker, and T cells can be further divided into 2 broad categories, based on the expression of CD4 or CD8 coreceptors. B cells: B cells can be identified by expression of CD19. NK cells: NK cells are typically identified by the coexpression of CD16 and CD56. Summary: Total T-cells (CD3+) B-cells (CD3-/CD19+) Natural killer (NK) cells (CD3-/CD56+CD16+) Helper/inducer (CD3+/CD4+) T-cell subset cytotoxic/suppressor (CD3+/CD8+) T-cell subset Total CD45+ lymphocyte count CD4:CD8 ratio ----------------------------- The absolute counts of lymphocyte subsets are known to be influenced by a variety of biological factors, including hormones, the environment, and temperature. The studies on diurnal (circadian) variation in lymphocyte counts have demonstrated progressive increase in CD4 T-cell count throughout the day, while CD8 T cells and CD19+ B cells increase between 8:30 a.m. and noon with no change between noon and afternoon. NK-cell counts, on the other hand, are constant throughout the day. Circadian variations in circulating T-cell counts have been shown to be negatively correlated with plasma cortisol concentration. In fact, cortisol and catecholamine concentrations control distribution and, therefore, numbers of naive versus effector CD4 and CD8 T cells. It is generally accepted that lower CD4 T-cell counts are seen in the morning compared to the evening and during summer compared to winter. These data, therefore, indicate that timing and consistency in timing of blood collection is critical when serially monitoring patients for lymphocyte subsets. Abnormalities in the number and percent of T (CD3, CD4, CD8), B (CD19), and NK (CD16+CD56) lymphocytes have been described in a number of different disease conditions. In patients who are infected with HIV, the CD4 count is measured for AIDS diagnosis and for initiation of antiviral therapy. The progressive loss of CD4 T lymphocytes in patients infected with HIV is associated with increased infections and complications. The Public Health Service has recommended that all patients who are HIV-positive be tested every 3 to 6 months for the level of CD4 T lymphocytes. Lymphocyte subset quantitation is also very useful in the evaluation of patients with primary immunodeficiencies of all ages, including follow-up for newborn screening for severe combined immunodeficiency and immune monitoring following immunosuppressive therapy for transplantation, autoimmunity, or any other relevant clinical condition where immunomodulatory treatment is used. It is also helpful as a preliminary screening assay for gross quantitative anomalies in any lymphocyte subset, whether related to malignancies or infection. The 2008 guidelines for diagnosis and treatment of Chronic Lymphocytic Leukemia (CLL) from the International Workshop on Chronic Lymphocytic Leukemia recommends changing the diagnostic criteria for CLL from an absolute lymphocyte count greater than 5 x 10(9)/L to a circulating B-cell count greater than 5 x 10(9)/L(8,9) previously defined in the 1996 National Cancer Institute (NCI) guidelines for CLL. This flow cytometric assay enables accurate quantitation of circulating B cells using a single platform technology with absolute quantitation through the use of flow cytometry beads. Sources: https://www.mayocliniclabs.com/test-catalog/Overview/9336#Clinical-and-Interpretive https://www.cancer.gov/publications/dictionaries/cancer-terms/def/t-cell https://www.rcpa.edu.au/Manuals/RCPA-Manual/Pathology-Tests/L/Lymphocyte-immunophenotyping References: Milioglou I, Kalaitzidou I, Ladomenou F. Interpretation of lymphocyte subset counts by the general pediatrician. Pediatr Int. 2019 Jan;61(1):16-22. doi: 10.1111/ped.13701. Epub 2018 Dec 10. PMID: 30248214.
Why use the CD57 test? The CD57 test is offered in some clinical laboratories and is being used by some health practitioners to evaluate and follow patients diagnosed with chronic Lyme disease. What is Lyme disease? Lyme disease, the most common vector-borne illness in the United States, is caused by Borrelia burgdorferi and transmitted by the bite of the Ixodes sp. tick (the deer tick). The disease usually begins with erythema migrans, an expanding skin lesion at the site of the tick bite. Within several days or weeks, there is hematogenous dissemination of the spirochetes, and patients may present with dermatologic, neurological, cardiac, and rheumatologic involvement. What is chronic lyme disease? Chronic Lyme disease is a controversial term applied to a broad spectrum of patients, including individuals with Lyme disease and those with post-Lyme disease syndrome (PLDS), as well as patients with no evidence of current or past Borrelia burgdorferi infection. PLDS is defined as the persistence or relapse of nonspecific symptoms (such as fatigue, musculoskeletal pain, and cognitive complaints) in patients who have had Lyme disease and have received an adequate course of antibiotic therapy. It has been reported that people with “chronic Lyme disease” have a decreased number of natural killer cells (NK cells), as defined by the CD57 marker. Although acute infections can be treated with antibiotics, failure to treat may result in a chronic, debilitating illness characterized by musculoskeletal and neurologic symptoms. Chronic Lyme disease may be difficult to treat, but also to diagnose What are white blood cells? White blood cells (=leukocytes) help the body to fight infections and other diseases. The human immune system consists of several different types of white blood cells with one category being called Lymphocytes. Lymphocytes attack antigens (foreign proteins). Lymphocytes consists of 3 subcategories of white blood cells known as B-Cells, T-Cells, and Natural Killer Cells. B-cells – responsible for antibody production T-cells – responsible for killing foreign invaders. natural killer (NK) cells – responsible for killing foreign invaders. Natural killer cells versus T-cells: Natural killer cells are the first line of defense against foreign pathogens and they belong to the innate immune system. They are not specific in their immune response and recognize a wide variety of pathogens. T-cells, on the other side, belong to the adaptive immune system. They are much more focused and highly specialized. What are CD markers? CD stands for cluster designation. CD is a glycoprotein molecule on the cell surface that acts as an identifying marker. Each different marker (or CD) on a cell is named with a number, which signifies the order in which the CD was discovered. Cells that have a certain kind of CD present on their surface are denoted as “+” for that CD type (e.g., a cell with CD57 markers on its surface is “CD57+”. What are CD57 cells? CD57 is a natural killer cell. A below-normal count of CD57+ cells has been associated with chronic Lyme disease. No one knows for sure why CD57+ NK cells are low in Lyme disease patients, but it is important to note that many disease states that are often confused with chronic Lyme (such as MS, systemic lupus, rheumatoid arthritis) are not associated with low CD57+ counts. Borrelia are believed to be capable of reducing the total amount of CD57 natural killer cells in the human body. It is generally believed that the lower the amount of CD57 natural killer cells in the body, the more chronic or progressive Lyme disease is, and the higher the amount, the closer a person is to remission. What are CD8 cells? The CD8 cells are generally referred to as T-cells, not to be confused with natural killer cells. Controversy around using this test: The utility of this test is controversial. Marques et. al. (2009 Clin. Vaccine Immunol. 16:1249-50) reported that there was no difference between the CD57 NK cell counts among patients with Lyme disease and normal controls. There have been instances where high amounts of CD57 natural killers cells have been found in those with chronic Lyme disease, and low amounts of CD57 natural killer cells have been found in those who were believed to be in remission. Possible treatment options: There are various stages of Lyme infection, and treatments differ according to the stage of infection. It’s important to be aware of the various treatment options so that you can help your doctor determine what’s right for you. Treatment options include one or multiple rounds of antibiotics (oral, intravenous, intramuscular, etc). When a patient is diagnosed with Chronic Lyme Disease, doctors work to develop an extended treatment plan. Treating Chronic Lyme can last months, years or even longer. Decisions about the treatment of the patient with chronic Lyme disease need to be individually shaped by the clinician’s experience, the patient’s clinical profile and history of antibiotic responsiveness, and the emerging medical literature. References: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725528/ https://academic.oup.com/cid/article/61/7/1084/289719 https://lymescience.org/wp-content/uploads/2018/11/CD57-unavailable.pdf https://www.sciencedirect.com/science/article/pii/S0399077X18306760 https://cvi.asm.org/content/16/11/1704 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196523/ https://canlyme.com/just-diagnosed/treatment/chronic-lyme-disease/ Disclaimer: The information on healthmatters.io is NOT intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. Reference Range(s): CD57+/CD3- of % Lymphs 1-10 % Lymphocytes CD57+/CD3- of % WBC 1-4 % WBC CD57+/CD3- Cells/uL 20-258 Cells/uL CD57+/CD3-/CD8- of % Lymphs 1-5 % Lymphocytes CD57+/CD3-/CD8- of % WBC 1-3 % WBC CD57+/CD3-/CD8- Cells/uL 20-114 Cells/uL CD57+/CD8- of % Lymphs 1-15 % Lymphocytes CD57+/CD8- of % WBC 1-4 % WBC CD57+/CD8-Cells/uL 20-248 Cells/uL
CD3 cells are total T lymphocytes
The absolute CD3 count — your total T-lymphocyte count.
The CD4 cells are Helper T-cells expressing both CD3 and CD4.
The CD4 cells are Helper T-cells expressing both CD3 and CD4.